在重症监护环境中复杂的腹腔内感染中使用斯福米:它是否改善了结果? 一个回顾性的观察性研究
Giovanni Genga1,2, Federico Ragni1, Maria Carolina Benvenuto1
1Infectious Diseases Clinica, Santa Maria della Misericordia Hospital, University of Perugia, 06100 Perugia, Italy.
Antibiotics (Basel, Switzerland)
|November 27, 2025
概括
在重症监护病房内,静脉注射菌素作为标准治疗腹腔内感染 (IAI) 的补充剂并没有显著改变临床反应或死亡率. 临床医生在更严重的病例中使用了菌素,这表明它在复杂的IAI管理中的作用.
科学领域:
- 关键护理医学 关键护理医学
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 腹腔内感染 (IAI) 带来了高发病率和死亡率的重大挑战.
- 斯福米辛是一种经批准的抗生素,用于治疗IAI的组合疗法.
- 评估静脉注射菌素在重症监护机构的影响对于优化IAI治疗至关重要.
研究的目的:
- 为了评估添加静脉注射福斯福米到IAI的组合疗法的影响.
- 为了比较临床反应和重症监护室 (ICU) 患者的住院死亡率.
- 确定与IAI患者死亡率相关的风险因素.
主要方法:
- 追溯性,观察性,单心性研究,包括104名ICU患者的IAI.
- 患者被分为两组:标准治疗 (A组) 和标准治疗加注射菌素 (B组).
- 主要终点:临床反应在7天和住院死亡率;次要:对死亡率的风险因素分析.
主要成果:
- 群体在人口统计上是同质的,但B组的初始临床状况更差.
- 7天后的临床反应 (81.2%对73.7%) 和住院死亡率 (27.1%对47.2%) 在两组之间是可比的.
- 查尔森并发症指数和败血症休克是死亡风险因素;有效的经验治疗是保护性的;斯福米辛没有显示直接的结果关联.
结论:
- 在IAI的标准治疗和福米辛联合治疗之间没有观察到显著的结果差异.
- 斯福米辛被用于患有更严重的疾病和延迟源控制的患者,这表明其用于复杂病例.
- 可能需要进一步的研究来确定福斯福米在严重腹部内感染中的特定作用.
相关概念视频
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
267
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
267
01:27Acute Pyelonephritis I: Introduction
421
Pyelonephritis is a bacterial infection that primarily affects the renal parenchyma and collecting system, including the renal pelvis, tubules, and interstitial tissue of one or both kidneys. It can be classified as either acute—a sudden, severe infection—or chronic, which refers to long-term or recurrent kidney infections.The primary cause of acute pyelonephritis (APN) is bacterial infection, with Escherichia coli accounting for approximately 70-80% of cases. Other bacteria, such...
421
01:25Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
453
Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
453
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
224
A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
224
01:17Urinary Tract Infection IV: Nursing Management
387
In managing urinary tract infections (UTIs) in nursing, a comprehensive assessment is essential. Begin by gathering subjective data, such as the patient’s complaints of dysuria (painful urination), urinary frequency, urgency, suprapubic pain, and any lower abdominal discomfort. This information can be complemented by questions regarding previous UTIs, sexual activity, and personal hygiene practices, which can provide insight into risk factors. Objective assessment should focus on signs...
387
01:30Pneumonia III: Complications and Assessment
752
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
752